Clinical case use bevacizumab for patient with metastatic ovarian cancer

Abstract

High incidence and mortality rate for ovarian cancer patients, short-term survival until relapse, repeated following surgeries and chemo- therapy, and also low survival rates make the problem of treatment of this pathology vital. Nowadays combination of platinum and paclitaxel (gemcitabine) in addition with targeted therapy (bevacizumab) is the most effective chemotherapy for first and second line of stages III and IV ovarians cancer. Considering high efficacy of these combinations aimed at the improving of the results of survival, further study of the use of bevacizumab in metastatic ovarian cancer therapy is necessary.М.Р. Оганян, О.В. ДавиденкоГБУЗ «Клинический онкологический диспансер No 1» Минздрава Краснодарского края, Краснодар Контакты: Мариэтта Рафаэловна Оганян [email protected]

Keywords

• metastatic ovarian cancer
• angiogenesis
• bevacizumab